云南白药
(000538)
| 流通市值：902.07亿 | | | 总市值：907.83亿 |
| 流通股本：17.73亿 | | | 总股本：17.84亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 11,602,596,895.18 | 41,186,999,090.31 | 30,654,214,209.01 | 21,257,102,896.02 |
| 营业收入 | 11,602,596,895.18 | 41,186,999,090.31 | 30,654,214,209.01 | 21,257,102,896.02 |
| 二、营业总成本 | 9,475,409,648 | 36,210,224,002.36 | 26,074,760,939.86 | 17,836,286,155.07 |
| 营业成本 | 8,048,363,101.82 | 29,032,923,195.82 | 21,439,589,799.52 | 14,697,868,069.29 |
| 税金及附加 | 58,641,693.75 | 234,100,213.88 | 168,628,336.49 | 125,773,653.15 |
| 销售费用 | 1,149,720,004.51 | 5,619,465,376.89 | 3,715,299,786.11 | 2,516,371,857.04 |
| 管理费用 | 130,505,111.34 | 1,020,080,152.22 | 555,274,908.29 | 363,479,043.45 |
| 研发费用 | 76,790,122.07 | 350,545,386.25 | 234,998,200.97 | 155,900,139.57 |
| 财务费用 | 11,389,614.51 | -46,890,322.7 | -39,030,091.52 | -23,106,607.43 |
| 其中:利息费用 | 5,085,418.24 | 24,049,890.09 | 15,215,722.1 | 10,739,501.71 |
| 其中:利息收入 | 10,427,785.54 | 90,467,001.34 | 75,016,226.69 | 49,581,264.78 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 16,376,374.37 | 110,489,468.71 | 81,760,362.06 | 70,037,496.76 |
| 加:投资收益 | 242,968,938.97 | 1,042,986,305.52 | 951,171,248.8 | 839,628,716.65 |
| 资产处置收益 | 1,025,221.36 | 8,167,595.81 | 3,036,533.62 | 2,552,729.83 |
| 资产减值损失(新) | -6,621,331.64 | -258,372,158.02 | -66,216,984.74 | -41,743,184.35 |
| 信用减值损失(新) | -71,455,718.12 | 58,066,387.77 | -13,090,132.2 | -98,382,642.61 |
| 其他收益 | 52,104,616.15 | 100,782,693.13 | 68,938,519.46 | 27,406,398.49 |
| 四、营业利润 | 2,361,585,348.27 | 6,038,895,380.87 | 5,605,052,816.15 | 4,220,316,255.72 |
| 加:营业外收入 | 2,967,869.41 | 24,951,555.82 | 18,588,012.77 | 17,525,440.99 |
| 减:营业外支出 | 3,674,264.33 | 20,576,232.96 | 8,542,285.23 | 5,969,854.92 |
| 五、利润总额 | 2,360,878,953.35 | 6,043,270,703.73 | 5,615,098,543.69 | 4,231,871,841.79 |
| 减:所得税费用 | 330,297,748.47 | 853,329,846.75 | 825,928,468.27 | 587,271,873.85 |
| 六、净利润 | 2,030,581,204.88 | 5,189,940,856.98 | 4,789,170,075.42 | 3,644,599,967.94 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 2,030,581,204.88 | 5,189,940,856.98 | 4,789,170,075.42 | 3,644,599,967.94 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 2,037,306,990.13 | 5,153,486,838.91 | 4,777,119,657.47 | 3,632,911,303.12 |
| 少数股东损益 | -6,725,785.25 | 36,454,018.07 | 12,050,417.95 | 11,688,664.82 |
| 扣除非经常损益后的净利润 | 1,965,172,511.31 | 4,864,568,403.16 | 4,549,939,286.91 | 3,460,915,449.48 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.14 | 2.89 | 2.68 | 2.04 |
| (二)稀释每股收益 | 1.14 | 2.89 | 2.68 | 2.04 |
| 八、其他综合收益 | -8,785,384.58 | -6,013,856.89 | 3,052,405.37 | 4,613,102.15 |
| 归属于母公司股东的其他综合收益 | -6,965,862.49 | -3,828,024.2 | 1,788,432.1 | 3,258,451.54 |
| 九、综合收益总额 | 2,021,795,820.3 | 5,183,927,000.09 | 4,792,222,480.79 | 3,649,213,070.09 |
| 归属于母公司股东的综合收益总额 | 2,030,341,127.64 | 5,149,658,814.71 | 4,778,908,089.57 | 3,636,169,754.66 |
| 归属于少数股东的综合收益总额 | -8,545,307.34 | 34,268,185.38 | 13,314,391.22 | 13,043,315.43 |
| 公告日期 | 2026-04-30 | 2026-04-01 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |